Suzetrigine for Lactation Safety

This trial explores how suzetrigine and its active ingredient are processed in the breast milk of breastfeeding mothers. Researchers aim to determine how much of the drug passes into breast milk and assess its safety for both mothers and their babies. Suitable participants include women who have been breastfeeding or pumping regularly, at least three times a day, and are 6 weeks to 12 months postpartum. Participants will receive a single dose of the medication and must maintain their milk supply by continuing to pump. The study aims to ensure the medication's safety during lactation. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to groundbreaking safety research.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research has shown that suzetrigine has been tested for safety in over 1,000 patients in various situations. These studies found it to be generally well-tolerated. However, specific information about its safety for breastfeeding mothers is not yet available. Suzetrigine binds strongly to proteins in the blood, which might reduce its passage into breast milk.

Unlike other treatments for lactation safety, Suzetrigine offers a novel approach because it focuses on ensuring the safety of medication use during breastfeeding without compromising the health of the infant. Current options often involve either avoiding certain medications or using those with a well-established safety profile, but Suzetrigine is being explored for its potential to expand safe medication choices for breastfeeding mothers. Researchers are particularly excited about its unique active ingredient, which aims to minimize any adverse effects on both mothers and their babies while maintaining therapeutic efficacy. This could significantly broaden the range of safe medications available for breastfeeding women, offering them more flexibility in managing their health.

Studies have shown that suzetrigine effectively treats sudden pain by blocking pathways that transmit pain signals in the body. Research from two trials confirmed it reduces pain with fewer side effects, such as nausea and dizziness, compared to opioids. However, specific information on suzetrigine's effects on breastfeeding mothers or their babies remains unavailable. In this trial, participants will receive a single dose of suzetrigine to determine its presence in breast milk and its safety for nursing mothers.¹²⁴⁶⁷